Chemotherapy-induced neutropenia does not correlate with DNA repair gene polymorphisms and treatment efficacy in advanced non-small-cell lung cancer patients

Clinical Lung Cancer

Volumn 12, Issue 4, 2011, Pages 224-230

  Iranzo, Vega ^a   Sirera, Rafael ^a,b   Bremnes, Roy ^c   Blasco, Ana ^a   Jantus Lewintre, Eloísa ^a   Tarón, Miquel ^d   Berrocal, Alfonso ^a   Blasco, Sara ^a   Caballero, Cristina ^a   Del Pozo, Nieves ^a   Rosell, Rafael ^d   Camps, Carlos ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITAT POLITÈCNICA DE VALÈNCIA   (Spain)

^c UNIVERSITY OF TROMSØ   (Norway)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Advanced disease; Chemotherapy; Efficacy to therapy; NSCLC; SNP

Indexed keywords

CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN 10; XERODERMA PIGMENTOSUM GROUP D PROTEIN 23; XRCC3 PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NEUTROPENIA; DNA REPAIR; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; GENE FREQUENCY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

EID: 79960360304     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.03.023     Document Type: Article

References (24)

1. Rapp E, Pater JL, Willan A, et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6:633-41.
2. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106:861-5. (Pubitemid 24278896)
3. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 1993; 11:1866-72. (Pubitemid 23304609)
4. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-94. (Pubitemid 29470650)
5. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8. (Pubitemid 34438899)
7. Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 1999; 80:1681. (Pubitemid 29389618)
8. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001; 91:2246-57. (Pubitemid 32552809)
9. Poikonen P, Saarto T, Lundin J, et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999; 80:1763-6. (Pubitemid 29389629)
10. Saarto T, Blomqvist C, Rissanen P, et al. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 1997; 75:301-5. (Pubitemid 27019578)
11. Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89:1837-42. (Pubitemid 37533256)
12. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6:669-77. (Pubitemid 41222757)
13. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001; 22:1437-45. (Pubitemid 32898701)
14. Camps C, Sirera R, Iranzo V, et al. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer 2007; 8:369-75. (Pubitemid 46924057)
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
16. National Cancer Institute. Cancer therapy evaluation program: Guidelines for the reporting of adverse drug reactions. Common toxicity criteria v2.0 (CTC), 1999. Available at: http://ctep.cancer.gov/reporting/CTC-3.htlm). Accessed March 23, 1998.
17. De las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17: 668-75.
18. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996; 14:2590-611. (Pubitemid 26300128)
19. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer 2002; 86:1297-302.
20. Gurney H. I don't underdose my patients.. do I? Lancet Oncol 2005; 6:637-8.
21. Kvinnsland S. The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 1999; 80:1681. (Pubitemid 29389618)
22. Cameron DA, Massie C, Kerr G, et al. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003; 89:1837-42. (Pubitemid 37533256)
23. Cortes EP, Holland JF, Wang JJ, et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974; 291:998-1000.
24. Yamanaka T, Matsumoto S, Teramukai S, et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer 2007; 97:37-42. (Pubitemid 47012089)